Merck Serono partners with Ono to treat cancer and MS

10/4/2011 | Genetic Engineering & Biotechnology News

Ono Pharmaceuticals and Merck Serono entered two agreements covering the former's ONO-4641, a midstage oral compound for multiple sclerosis, and the latter's Stimuvax, a late-stage immunotherapy for cancer. The first deal gives Merck Serono worldwide rights excluding Taiwan, South Korea and Japan to ONO-4641 for $18.75 million upfront plus milestone fees. For the second contract, Ono will pay Merck Serono about $6.7 million upfront for Japanese co-development and co-commercialization rights to Stimuvax.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA